U.S. Markets close in 6 hrs 23 mins

Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock?

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So shareholders might well want to know whether insiders have been buying or selling shares in Cortexyme, Inc. (NASDAQ:CRTX).

Do Insider Transactions Matter?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. However, most countries require that the company discloses such transactions to the market.

We don't think shareholders should simply follow insider transactions. But it is perfectly logical to keep tabs on what insiders are doing. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

View our latest analysis for Cortexyme

The Last 12 Months Of Insider Transactions At Cortexyme

Over the last year, we can see that the biggest insider purchase was by Independent Director David Lamond for US$2.5m worth of shares, at about US$56.42 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$46.23). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

Cortexyme insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$49.28. These transactions suggest that insiders have considered the current price attractive. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

Cortexyme is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Does Cortexyme Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Cortexyme insiders own about US$445m worth of shares (which is 33% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The Cortexyme Insider Transactions Indicate?

The fact that there have been no Cortexyme insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. With high insider ownership and encouraging transactions, it seems like Cortexyme insiders think the business has merit. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Cortexyme. Be aware that Cortexyme is showing 3 warning signs in our investment analysis, and 1 of those is potentially serious...

Of course Cortexyme may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.